The online version of this article (doi:10.1186/1476-9255-9-25) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
LDW and CS developed the research hypothesis and study methodologies, LDW carried out the laboratory analyses, CR conducted the statistical analyses, and SA assisted in the interpretation of findings. All authors contributed toward the writing of the final manuscript.
Barth Syndrome (BTHS) is a serious X-linked genetic disorder associated with mutations in the tafazzin gene (TAZ, also called G4.5). The multi-system disorder is primarily characterized by the following pathologies: cardiac and skeletal myopathies, neutropenia, growth delay, and exercise intolerance. Although growth anomalies have been widely reported in BTHS, there is a paucity of research on the role of inflammation and the potential link to alterations in growth factors levels in BTHS patients.
Plasma from 36 subjects, 22 patients with Barth Syndrome (0.5 - 24 yrs) and 14 healthy control males (8 - 21 yrs) was analyzed for two growth factors: IGF-1 (bound and free) and Growth Hormone (GH); and two inflammatory cytokines IL-6 and TNF-α using high-sensitivity enzyme-linked immunosorbent assays.
The average IL-6 and IL6:IGF ratio levels were significantly higher in the BTHS (p = 0.046 and 0.02 respectively). As for GH, there was a significant group by age interaction (p = 0.01), such that GH was lower for BTHS patients under the age of 14.4 years and higher than controls after age 14.4 years. TNF-α levels were not significantly different, however, the TNF-α:GH was lower in BTHS patients than controls (p = 0.01).
Comparison of two anabolic growth mediators, IGF and GH, and two catabolic cytokines, IL-6 and TNF-α, in BTHS patients and healthy age-matched controls demonstrated a potential imbalance in inflammatory cytokines and anabolic growth factors. Higher rates of IL-6 (all ages) and lower GH levels were observed in BTHS patients (under age 14.5) compared to controls. These findings may implicate inflammatory processes in the catabolic nature of Barth Syndrome pathology as well as provide a link to mitochondrial function. Furthermore, interactions between growth factors, testosterone and inflammatory mediators may explain some of the variability in cardiac and skeletal myopathies seen in Barth Syndrome.
Authors’ original file for figure 112950_2011_238_MOESM1_ESM.pdf
Authors’ original file for figure 212950_2011_238_MOESM2_ESM.pdf
Authors’ original file for figure 312950_2011_238_MOESM3_ESM.pdf
Authors’ original file for figure 412950_2011_238_MOESM4_ESM.pdf
Authors’ original file for figure 512950_2011_238_MOESM5_ESM.pdf
Bateman C: Little known killer: Barth syndrome. S Afr Med J. 2003, 93: 249-250. PubMed
Jurasinski CV, Vary TC: Insulin-like growth factor I accelerates protein synthesis in skeletal muscle during sepsis. Am J Physiol. 1995, 269: E977-981. PubMed
Mitsuyama K, Sata M, Tanikawa K: Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn. 1991, 26: 20-28. PubMed
Lacativa PG, Farias ML: Osteoporosis and inflammation. Arq Bras Endocrinol Metabol. 54: 123-132.
R Development Core Team RFfSC: R: A language and environment for statistical computing. 2008
Rubin DA, McMurray RG, Harrell JS, Hackney AC, Haqq AM: Do surrogate markers for adiposity relate to cytokines in adolescents?. J Investig Med. 2008, 56: 786-792. PubMed
Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR: Resting and exercise-induced IL-6 levels in children with Type 1 diabetes reflect hyperglycemic profiles during the previous 3 days. J Appl Physiol. 108: 334-342.
Crowe FL KT, Allen NE, Appleby PN, Overvad K, Grønbæk H, Tjønneland A, Halkjær J, Dossus L, Boeing H, Kröger J, Trichopoulou A, Zylis D, Trichopoulos D, Boutron-Ruault MC, de Lauzon-Guillain B, Clavel-Chapelon F, Palli D, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Gram IT, Rodríguez L, Jakszyn P, Molina-Montes E, Navarro C, Barricarte A, Larrañaga N, Khaw KT, Rodwell S, Rinaldi S, Slimani N, Norat T, Gallo V, Riboli E, Kaaks R: Association between height, BMI and blood levels of IGF-I, IGFBP-1, IGFBP-2 and IGFBP-3. Annu Hum Biol. 2010
Weigert C, Dufer M, Simon P, Debre E, Runge H, Brodbeck K, Haring HU, Schleicher ED: Upregulation of IL-6 mRNA by IL-6 in skeletal muscle cells: role of IL-6 mRNA stabilization and Ca2 + −dependent mechanisms. Am J Physiol Cell Physiol. 2007, 293: C1139-1147. 10.1152/ajpcell.00142.2007. CrossRefPubMed
Savage MO, Burren CP, Rosenfeld RG: The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf). 2010, 72: 721-728. CrossRef
- Higher IL-6 and IL6:IGF Ratio in Patients with Barth Syndrome
Lori D Wilson
Cyril S Rakovski
Christina D Schwindt MD
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II